Home > Browse Issues > Vol.38 No.9
Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer
Xie Yuqiong, Li Chunchun, Cao Jiang*
Clinical Research Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
Abstract: Lung cancer is currently the top malignancy with the highest morbidity and mortality worldwide，most of which belongs to non-small cell lung cancer (NSCLC). Application of tyrosine kinase inhibitors (TKIs) has become an important therapeutic approach targeting epidermal growth factor receptor (EGFR) for treatment of NSCLC patients. However， the arising acquired-resistance significantly limits the efficacy of these targeting agents.Besides factors at molecular level such as genetic mutations， a number of investigations in recent years showed that autophagy played an important role in acquired-resistance to EGFR-TKIs of NSCLC. In this review， we focus on summarizing recent advances in autophagy and acquired-resistance to EGFR-TKIs of NSCLC， aiming to provide more ideas to overcome the autophagy-associated acquired-resistance to EGFR-TKI in NSCLC treatment.
CN
EN